We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Crown Bioscience Expands Operations and Re-Brands UK Site

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Crown Bioscience, Inc. has announced that it will double the capacity of the recently acquired PRECOS (Preclinical Oncology Services Limited) facility and will rename the site Crown Bioscience UK Ltd. (Crown UK). In addition, it was announced that Mike Prosser, Executive Director at Crown Bioscience has been appointed General Manager for Europe, responsible for leading both the next stage of its UK development as well as Crown’s continued growth in Europe.

These moves mark the completion of the PRECOS merger into the Crown organization, while the increased capacity represents a significant investment and long-term commitment to both its UK and European businesses.

The expansion of the Nottingham site will see the facility nearly double its operational footprint, encompassing both in vitro and in vivo capabilities, and is scheduled for formal opening on February 13th 2015.

In parallel, the UK site will now become Crown's center of excellence for models of Hormone Related Cancers (Breast, Prostate, Ovarian), while continuing to provide a wide variety of oncology services - both on-site and through accessing the global Crown network - to clients around the world.

Dr. Jean-Pierre Wery, President of Crown Bioscience, commented; “Since the acquisition, Crown has been working to fully integrate the talents and resources of the company into the organization. These changes, in particular the opening of the new facility, will help us lead the way in the study of Hormone Related Cancers, as well as strengthening our position in Europe.”

Mike Prosser, the newly appointed GM, added; “Since the merger, investment in Crown UK has been key to the advancement of Crown Bioscience’s service portfolio, such as the development of an irradiation treatment platform for preclinical screening of drug-irradiation combination therapies. In 2015 we aim to continue our expansion of service provision, complimenting both the new therapeutic focus and expanded capacity of Crown UK, and in doing so leveraging and supplementing Crown’s arsenal of services and capabilities.”

The acquisition of Crown UK in 2013 was significant in positioning Crown Bioscience as the world’s premier oncology contract research organization, offering a comprehensive range of services and now a key supplier of Oncology and CVMD services with a global footprint, spanning three major continents including North America, Europe and Asia Pacific.

With the recent expansion of the research center in North Carolina, strengthening the company’s presence in North America, the expansion of the U.K. facility is part of Crown’s wider strategy to reinforce and increase operations within Europe.